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Summary 
Depression measurement in cancer care is complex and inconsistent. It is difficult for 
investigators to select the best–performing tool. We conducted a meta-review to 
integrate the findings of reviews of patient-report depression measures used as 
screeners or case-finders in oncology. We searched Medline, PsycINFO, EMBASE 
and grey literature from 1999-2014. We identified 19 reviews representing 372 
primary studies assessing more than 50 depression measures. We used 11 high-
quality reviews to guide our analysis, which was organized by measurement goal and 
target population. The Hospital Anxiety Depression Scale was the most 
recommended, and criticized, depression screener. Few reviews evaluated case-
finding performance or measure responsiveness, or measure suitability for particular 
populations. This meta-review demonstrates that the available measure selection 
advice is conflicting. By being fully cognizant of the benefits and limitations of 
depression measurement, investigators can improve the accuracy of their data and 
achieve more sophisticated interpretations of their findings. 
 
Funding None.  
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Introduction 
Psycho-oncology has seen an exponential rise in research documenting the 
prevalence, measurement and experience of depression in cancer.3,4 MedLine records 
that ‘depression’ and ‘cancer’ were addressed together in an average of 192 
citations/year in the 1980’s, rising to an average of >1000 citations/year between 
2006-2015.5,6 Mirroring this rise, clinicians and researchers have utilized numerous 
patient-reported outcome measures to assess depression in individuals affected by 
cancer.4,7,8,9  
 
Unrecognized and untreated depression can have deleterious implications for long 
term quality of life,11,12 treatment adherence13 health service use,14,15 requests for 
death,11 and mortality.16-18 Opinion leaders therefore often recommend that all 
patients be evaluated for depressive symptoms at regular intervals across the 
trajectory of cancer care.12 Accurate and timely measurement of depression can 
ensure that the prevalence of depression across populations and stages is neither 
under- nor over-estimated.19,20 This data is needed to inform clinical practice and the 
allocation of appropriate resources to psychosocial services.3,19 
 
Available depression measures, however, yield differing data,21 with one meta-
analysis of 211 studies, using only 4 different depression measures,  reporting a 
range of 8% to 24% cancer patients affected by depression.22 It is not possible to 
elucidate whether this variability is due to actual differences in depression 
prevalence across cancer types or stages, is an artefact of the instrument used in each 
study,22 or is a function of each study’s characteristics (eg, sample size and 
representativeness).6,23 The use of a wide range of depression measures in clinical 
practice and research across studies has prevented simple cross-population and cross-
cultural comparisons.7,24 Also lost has been the ability to pool data,8 and to compare 
outcomes across cancer types,22 across time,8 and across disease stages.24 
 
Numerous reviews of depression measures, as well as evaluation tools to assess 
measure quality, are available. Available reviews however differ in focus (eg, 
providing a generic summary, or systematically appraising evidence) and methods 
(eg, their search, appraisal, synthesis, and analysis).25 The IPOS Research 
Committee therefore conducted a meta-review (an ‘overview of reviews’ or 
For measures to 
assess 
depression see 
http://www.scal
esandmeasures.
net/search.php 
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‘umbrella review’25) of depression outcome measures used as screeners or case-
finders in adults with or recovering from cancer. Meta-reviews present a unique 
approach to knowledge integration, enabling the aggregation and synthesis of 
multiple reviews into a single document.26 They are particularly useful for exploring 
consistency of findings across reviews and revealing consensus.25,27 The aims of this 
meta-review were: 
1. To identify and critically appraise, using a gold-standard checklist, the 
available reviews of depression measures for use with adults with cancer;28  
2. To aggregate the results of the captured reviews into one accessible report;  
3. To identify consensus between reviews; and 
4. To identify a set of ‘candidate measures’ for further detailed consideration of 
their appropriateness for measuring depression in adults affected by cancer. 
 
Methods 
Search strategy and selection criteria 
This meta-review was undertaken following the steps recommended by Cooper and 
Koenka.27 After formulating the problem, the steps included (1) searching the 
literature, (2) gathering information from articles/reports, (3) evaluating the quality 
of the evidence, (4) analyzing and integrating the outcomes of research, (5) 
interpreting the evidence, and (6) presenting the results. 
 
Review selection (Step 1: Searching the literature27) 
We searched three databases of peer-reviewed journals, two grey literature 
databases, Google Scholar and reference lists of eligible reviews, for studies 
published between 1999 and 2014 (detailed in Panel A). The 15-year timeframe 
aligns with other reviews,5,29 and ensured that depression measures developed prior 
to 1999, but used (and reviewed) in the past 15 years, were included.  
 
Inclusion/exclusion criteria 
Domains assessed: The meta-review aimed to capture reviews of patient-reported 
outcome measures of depression in adults with, or recovering from, cancer using a 
standardized paper or online questionnaire. Reviews of measures that included one 
or more subscales assessing depression (eg, quality of life outcome measures with a 
depression subscale) were eligible if the subscale’s psychometric properties were 
For information 
about the IPOS 
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reported separately from the performance of the complete measure. Reviews 
assessing outcome measures for specific cancer diagnoses (eg, breast cancer-specific 
measures) were also eligible, as were reviews assessing ‘ultra-short’ (1-4 items) and 
‘short’ (5-20 items) instruments.4 
 
Types of reviews: We included published systematic (as defined by the PRISMA 
Statement; with or without meta-analyses)28 and narrative reviews summarizing data 
collected from adults (aged 18+ years) diagnosed with any type of cancer, at any 
stage of the cancer experience (including palliative care and survivorship). Given the 
evidence that ‘grey literature’ plays an important role in guiding policy and 
practice,30,31 we also included reviews published in reports, discussion papers, 
briefings, and practice guidelines.30,31 Reviews of measures used for screening (ie, to 
‘rule-out’ patients without depression with minimal missed cases [false negatives])7, 
case-finding (ie, to ‘rule in’ those who have depression with minimal false 
positives)7 and assessment (ie, to determine the extent of depressive symptoms) were 
eligible.32 
 
Exclusions: We excluded primary studies and reviews of non-questionnaire 
measures, such as face-to-face or telephone-delivered clinical interviews. There is a 
lack of depression research33-36 in non-English speaking populations, however we 
restricted the meta-review to those published in English because expert review was 
not possible in other languages and translation was beyond the scope of the project. 
We excluded other related domains, such as sadness, grief, suicidal ideation, 
melancholy, hopelessness, demoralization, adjustment disorder, and quality of life. 
We excluded measures of generalized ‘distress’ due to their lack of specificity in 
terms of psychological morbidity, unless they were specifically evaluated as 
depression screeners or case-finders.37 We also excluded reviews on individuals 
without a cancer diagnosis (eg, those at increased risk of cancer, partners, caregivers, 
and family members). When multiple reviews published by the same first author 
were captured, we utilized the article with the highest quality (defined by the 
PRISMA statement), unless the reviews addressed substantively different research 
questions. For example, the 2010 Luckett, Butow 5 review was included rather than 
their 2012 review38 due to substantial overlap in research questions, methodology 
and findings. 
For more 
information about 
PRISMA see 
http://www.prisma
-statement.org/ 
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Data extraction and classification (Step 2: Gathering the information27) 
CEW and EGR reviewed all abstracts and full-text articles. Consensus regarding 
inclusion or exclusion of articles was achieved by discussion, and for remaining 
disagreements, by consultation with all authors. Captured articles were categorized 
by their primary purpose as assessing depression measures as i) screening tools, ii) 
case-finding tools, or iii) on their capacity  to detect change (table 1). We extracted 
the following data for screening tools: sensitivity and specificity (pooled or 
weighted), screening utility index, recommended ‘cut-point’ scores, and the review’s 
recommendations. For articles that did not report summary sensitivity and specificity 
scores, we calculated medians and ranges of scores where possible. Data collected 
from reviews assessing case-finding capacity included: case-finding area under the 
curve (AUC) and positive utility index (UI+). Data gathered from reviews assessing 
capacity to detect change included: weighted score for responsiveness and effect 
sizes detected.  
 
Critical appraisal (Step 3: ‘Evaluating the quality of the evidence27) 
CEW and EGR independently appraised the captured reviews using the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement 
criteria,28 supplemented by the PRISMA Explanation and Elaboration document.39 
When the investigators disagreed on any assessment, the issue was resolved through 
discussion with each other or with all authors. We decided, a priori, to focus our 
analysis on reviews that met 20 or more of the 27 PRISMA criteria because a recent 
assessment of the quality of PRISMA reporting in 236 reviews showed that 
approximately 70% of reviews meet 20 of the 27 PRISMA criteria.40 Only measures 
recommended by at least one high-scoring review were considered as possible 
candidate measures suitable for detailed assessment. Narrative reviews were not 
critically appraised because their purpose and methods differ from systematic 
reviews.41 
 
Results (Step 4: Analyzing the outcomes27) 
We identified 19 eligible reviews with good inter-rater reliability, including 12 
systematic and 7 narrative reviews (figure 1). The captured reviews represented 372 
original studies and assessed more than 50 depression measures. The Medline-
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EMBASE-PsychInfo search was most effective, yielding 78·9% sensitivity (15/19 
eligible reviews were captured with these searches) and 10·3% specificity (15 
eligible articles were captured out of 145 abstracts). Reviews originated from the 
United States (n=8), the United Kingdom (n=6), Australia (n=3), Canada (n=1), and 
the Netherlands (n=1), and focused on mixed cancer diagnoses, or on a specific 
cancer population (eg, older patients11,42). The goals of each review varied. Nine 
reviews assessed the suitability of depression measures as screening 
tools,1,4,5,7,8,19,22,43,44 while three assessed their suitability for case-finding.7,43,44 
Several reviews examined appropriate cut-points of specific measures,8,19,45,46 while 
others examined their usefulness in particular populations (eg, geriatric patients11,42). 
One review assessed the responsiveness of depression measures in detecting the 
effect of psychological interventions.5 One review assessed the performance of 
measures across five stages in the cancer trajectory,8 while others focused on mixed 
diagnoses and treatment stages.3,5-7,19,20,22,43-47 
 
Critical appraisal 
Table 2 summarizes the critical appraisal of each systematic review. All systematic 
reviews provided a sound rationale, a structured summary of findings, a description 
of their objectives and some discussion of findings (n=12). The PRISMA criteria 
least likely to be met were assessing the risk of bias within and across studies (four 
reviews assessed bias within studies4,7,19,22 and four assessed bias across studies4,43-
45). Five reviews failed to acknowledge their limitations and no review provided 
review protocol/registration details, suggesting that protocol registration for reviews 
is not yet common practice.48 Eleven of the 12 systematic reviews met at least 20 of 
the PRISMA criteria. The findings of high scoring reviews are summarized in Tables 
3-5. Tables 6 and 7 present the findings of lower scoring systematic reviews and the 
narrative reviews. 
 
Aggregation of meta-review results (summary of high scoring reviews’ 
recommendations) 
Screening 
The Hospital Anxiety and Depression Scale (HADS) was the most widely evaluated 
measure, with nine reviews assessing the HADS against other measures,1,4,5,7,22,42,43 
or alone.19,44 Positive features reported included its popularity (enabling cross-study 
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comparisons),6,8 and its ability to perform adequately across different stages of the 
cancer trajectory.8 The HADS was described as performing well in identifying major 
depression within pre-treatment (with a cut-point of 7 for the HADS-Depression 
subscale [HADS-D]) and post-treatment populations (cut-point between 9 and 11 for 
HADS-D).8 The most commonly-used threshold to determine depression prevalence 
during active treatment was a subscale score of 8 or above,8,19,22 although this cut-
point was poorly supported in one review.19 Each of the HADS subscales received 
moderate screening utility index scores for depression in one review (ranging from 
0·65-0·71),7 although these figures vary substantially across reviews.7,44 
 
Several reviews converged on the limitations of the HADS, highlighting the 
differing performance between the HADS-Total scale (HADS-T), the HADS-
Anxiety subscale (HADS-A), and the HADS-D,7 and the variability in recommended 
cut-points (ranging from 4 to 11).4,6,8,15,19 Mitchell and colleagues also suggested that 
the HADS-T or HADS-A (rather than the HADS-D) could be used as the first choice 
for a depression screening measure.44 HADS-A may also perform as well as HADS-
T in identifying depression in palliative care,1  although four reviews argued that the 
HADS was least suited for advanced cancer patients and for those receiving 
palliative care.1,4,7,8  
 
Several reviews assessed the screening performance of the Beck Depression 
Inventory (BDI), and/or its variations (the BDI-II and the BDI-short form, BDI-
SF).1,4,5,7,8,15,22,42,43 In each case, the BDI’s performance was considered in 
comparison with other measures. Reviews assessed the BDI favourably,  
highlighting its generalizability across cancer types and disease stages,4 its adequate 
screening performance7 and its potential usefulness in older patients.42 One review 
described the BDI as ‘excellent’ for a long measure, due to its good reliability and 
validity.4 Several reviews noted that the BDI has appropriate sensitivity and 
specificity,1,4,7,8 although some evidence suggests it has poorer specificity before and 
after cancer treatment.8 The BDI, however, is limited somewhat by its length (21 
items), reducing its acceptability.4,43 It also has a longer recall period (two weeks), 
potentially limiting its usefulness in some contexts.42  The BDI has also been 
criticized for including items with a somatic emphasis.5 The BDI-SF, with only 13 
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items may address some of these limitations; however, it may not perform as well 
psychometrically.4 
 
Several reviews evaluated ultra-short depression screeners, such as the Distress 
Thermometer (DT).7,38,45,47 Despite not specifically targeting depression, the DT 
showed good sensitivity and specificity as a depression screener and had high 
clinical acceptability in one review,7 and good sensitivity to change in another.4 Its 
performance also appeared comparable to the Brief Symptom Inventory-18 items 
(BSI-18) and General Health Questionnaire-12 items (GHQ-12) in palliative care.8 
However, given the potential high rates of false-negatives when using the DT, one 
review recommended the DT (and other ultra-short tools) not be used in isolation for 
depression screening.7 
 
Three reviews highlighted positive features of the Zung Self-Rating Depression 
Scale (ZSDS) (including being able to assess mood variation and having predictive 
validity data available).8,42,43 However, one review reported that it had good 
specificity, but poor sensitivity, at the time of cancer diagnosis.8 The Patient Health 
Questionnaire-9 (PHQ-9) was also evaluated by three reviews.4,5,42 Vodermeier and 
colleagues4 recognized its strong psychometric properties in medical populations, 
however rated it poorly due to low reliability and validity in cancer patients. Nelson 
and colleagues argued that the recall length of two weeks makes it less useful, for 
geriatrics in particular.42 Some PHQ-9 questions were highlighted as less appropriate 
for those undergoing active treatment (ie, in regards to sleep, fatigue, appetite, 
concentration, and restlessness).5  
 
Three reviews provided a positive appraisal of the Edinburgh Depression Scale 
(EDS) or the Brief Edinburgh Depression Scale (BEDS).1,4,8 In palliative care, one 
review recommended the EDS due to the absence of somatic items,1 with another 
arguing that the EDS can perform better than the HADS in this population.4 The 
Center for Epidemiologic Studies Depression Scale (CES-D) was evaluated by two 
reviews.4,42 It was the highest ranked short tool in one review (particularly the 
negative affect subscale).4 Although comprehensively evaluated, Nelson and 
colleagues argued that it was less suitable for geriatric patients because it includes 
only two of the most common seven depression symptoms in geriatric patients.42 
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One review described the General Health Questionnaire-28 (GHQ-28) as ‘excellent’ 
due to its high sensitivity and specificity, however the authors also expressed 
concerns about its length.4 Despite its good screening performance, one review 
expressed caution regarding its use during active treatment because of a lack of 
validation studies.8 The 12-item version of the GHQ (GHQ-12) was reviewed as 
‘good’ by Thekkumpurath and colleagues,1 although they reported it had inferior 
psychometric properties to the HADS in advanced cancer.  Few studies have 
reported GHQ-12 parameters, making it difficult to compare with other tools.1 The 
screening performance of the remaining scales was assessed in too few reviews to 
draw conclusions regarding their usefulness. 
 
Case-finding 
Evidence for the case-finding performance of depression measures was rare and less 
convincing, with only three reviews evaluating case-finding performance. One 
review assessed the HADS alone,44 while two compared the performance of multiple 
measures.7,43 Mitchell and colleagues (2010) reported that all HADS subscales had 
poor case-finding utility indices (ranging from 0·27-0·29).44 The remaining reviews 
reported moderate case-finding indices for the HADS.7,43 However, while the HADS 
indices were higher than the DT indices in both reviews,7,43  they were lower than 
that calculated for the BDI-II, which was graded as having mid-level evidence for 
case-finding capacity.7 Few data were available regarding the case-finding 
performance of depression measures for different populations or at different 
treatment stages, however there was some evidence that the BDI-18 did not perform 
as an effective case-finder in palliative care.7,43 
 
Responsiveness 
One review assessed the capacity of depression measures to detect treatment effects 
after participation in randomized controlled trials of psychological interventions.5 
The CES-D, the HADS, and the POMS-SF received the highest weighted scores (out 
the 16 measures assessed). The CES-D was most highly endorsed for studies in 
which depression was the sole focus, with an average detected effect size of -0·27 
(ranging from -0·36 to -1·04). The length of the CES-D (20 items) was highlighted 
as a limitation. The HADS was the best supported measure if the study had a broader 
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focus, such as for studies also assessing anxiety, mixed affective disorders or general 
distress. In these studies, the detected depression effect sizes averaged 0·45 (range 
0·1 to 0·97). HADS was however, considered less suitable for detecting minor 
depression.5 The POMS-37 received a good score (ranked third) due to its good 
validity and reliability, although the reviewers highlighted that both the HADS and 
POMS-SF may be less suitable than the CES-D because they rely more heavily on 
anhedonia.5 
 
Consensus and discordance between reviews (Step 5: Interpreting the evidence27) 
Table 8 summarizes the positive and negative features of the measures considered in 
this meta-review. Figures 2 and 3 present specific recommendations and cautions 
against each reviewed measure (organized by goal of measurement and by target 
population). No candidate measure was recommended by all reviews, nor did 
reviews unanimously recommend any one measure for a particular population or a 
specific time-point. Instead, the reviews agreed that every measure had important 
positive features, balanced by significant limitations. Many of the highlighted 
positive features and disadvantages of each measure were common across reviews. 
For example, multiple reviews highlighted the benefits associated with the popularity 
of the HADS (for cross comparisons),6,8 and agreed that the variability of 
recommended HADS cut-points was a limitation.4,8,19,22,46 Several reviews also 
agreed that the HADS was less well suited for palliative care and advanced cancer 
patients.1,8,44 There were insufficient independent reviews of the case-finding ability 
and responsiveness of depression measures to identify consensus between reviews. 
 
There were several disagreements between reviews regarding screening. When 
considering the HADS for example, it was unclear which scale or subscale (HADS-
T, HADS-D or HADS-A) was most suitable, particularly since different reviews 
assessed one, or each of the scales/subscales.7 Regarding the BDI and the CES-D, 
each was described as potentially useful for older, terminally ill patients,11 yet were 
also highlighted as less suitable for this population.42 The remaining measures were 
assessed by too few reviews to enable the identification of any disagreements 
regarding their suitability for screening, case finding, and detecting change. 
 
Discussion 
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In conducting this meta-review, the IPOS Research Committee hoped to ensure that 
investigators are utilizing the best performing measures, encourage consistency 
across data collection and reporting, and create future opportunities for cross-study 
comparisons. However, depression measures that were commonly recommended by 
some reviews were criticized by others.4,20 No review provided unqualified support 
for the adoption of any measure, and there were no measures identified as ideal for 
all types of patients and time points. The HADS was most often considered an 
acceptable depression screener and was most thoroughly evaluated,1,4,7,8,44 although 
it remains unclear whether the HADS-D, HADS-T, or even the HADS-A, is the best 
choice.44 Some captured reviews also recommended the CES-D, both for 
screening,4,5 and for detecting change.5 Reviews assessing case-finding capacity 
were rare, with the BDI-II being recommended if no verbal assessment is possible.7 
Panel B places these findings into context. 
 
This meta-review identified several measures as having particular potential for 
specific time points/populations. In palliative settings, the EDS (or BEDS) and the 
DT appear promising.1,8 The HADS appears less useful in this population, due to its 
focus on anhedonia,5 although generally the HADS is appraised positively because 
of its reduced reliance on somatic symptoms.20 Interestingly, there is some evidence 
to suggest that omitting somatic symptoms from depression screeners does not 
significantly improve the performance of common depression measures.7,49 
 
Despite many published studies attributing disappointing findings to floor or ceiling 
effects,50 the captured reviews did not address the risk of floor/ceiling effects in each 
measure. This is a significant limitation of many fixed length tools that might be 
overcome by computer adaptive testing (CAT). Given their recent development 
however, this meta-review failed to capture reviews of CAT measures of 
depression.51 CAT utilizes computer-aided logic, such that participants’ responses to 
previous items are used to select the most informative next item from a pool of 
possible items. CAT can reduce floor/ceiling effects because individuals at the top or 
bottom of a scale receive items that are targeted toward their level, improving 
precision and clinical relevance in comparison to the fixed length tools considered 
here.50,52 Given the rapid progress of the patient-reported outcome measurement 
information system (PROMIS) initiative,53 and the European Organisation for 
13 
Research and Treatment of Cancer (EORTC) project,54 it is possible that these 
approaches may complement, or even replace, the fixed length outcome measures 
assessed in this meta-review.7 
 
Despite identifying some evidence supporting the use of several depression measures 
in cancer, this meta-review also revealed major challenges faced by the screening 
and case-finding field. Patient-reported measures of depression can be useful to 
facilitate early detection,55 can cost less than structured clinical interviews5 and can 
be used across centers and countries.4 However, without effective after care, even the 
best performing measures will be of minimal benefit to patients.56 Indeed, many 
argue that screening should only be conducted in settings where there are appropriate 
resources available for in-depth assessment and treatment of those identified as in 
need.56-58  Only a minority of cancer centers has implemented routine screening into 
practice,4 and there is a dearth of implementation studies that demonstrate direct 
benefits to patients from screening.7,43,44 It is also possible that currently available 
screeners are least suitable for those who may have the greatest need (eg, non-
English speaking, and socially and economically disadvantaged, patients). It is 
important too, to recognize that all measures miss positive cases and falsely identify 
negative cases, both of which can have deleterious impacts. 
 
The potential role of alternative approaches to identifying patient needs for help with 
depression therefore warrants further consideration. It may be simpler in many cases 
to directly ask patients what they need, face-to-face.58,59 It is also possible that 
different measures or approaches may be appropriate for research versus clinical 
care.4 More work exploring measure acceptability from clinicians’ perspectives 
would be useful in this regard, as there is some evidence that clinicians find 
depression measures less acceptable than patients.53,54 Indeed, many continue to rely 
on their clinical judgement43,44 given that no patient-report measure has 100% 
concordance with clinical interview15,60 and that most guidelines recommend 
screening should be used in conjunction with thorough clinical assessment 
anyway.1,6,32,44 
 
Finally, given the often significant overlap between depression symptoms and other 
outcomes (such as distress, anxiety, fatigue, and pain), multidimensional assessment 
For information 
about PROMIS 
and EORTC 
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might also be more useful than focusing on the single construct of 
depression.4,8,15,61,62 In practice, clinicians are rarely solely interested in depression, 
potentially limiting the relevance of this meta-review to clinical practice.56 However, 
assessment of multiple dimensions within one measure can create statistical and 
clinical challenges in interpreting the data,63 suggesting that there still is a role for 
depression-specific measurement when it is the primary focus of a research project.  
 
Future research 
Further studies providing head-to-head (within sample) comparisons between 
measures and in comparison to clinical interviews are needed. There is a dearth of 
research assessing depression measures’ case-finding ability and responsiveness. 
Further work is needed to investigate the practical usefulness and clinical 
acceptability of depression measures. For many patients, depression may not be their 
primary concern, with practical needs, such as support with financial difficulties, and 
family and social concerns, often being more highly endorsed as core concerns for 
patients than depression.7,34,59 Recent research also suggests that that anxiety may be 
of greater importance to patients than depression, especially for cancer survivors.64,65 
The most useful screeners therefore might have a broader focus, beyond depression, 
and may also benefit from an assessment of patients’ desire for help with the 
concerns they endorse.59   
 
Additional population-specific work is also warranted. Some groups are more likely 
to under-report depression (eg, older patients, patients from different cultures, and 
those whose primary language is not English), meaning that measure performance 
may vary across groups.11,42 One review reported that two-thirds of their reviewed 
studies did not report the race/ethnicity of their sample, or specifically targeted a 
homogenous English-speaking sample, highlighting the literature dearth in this 
area.34 Furthermore, recorded depression prevalence varies widely among patients 
with different tumor types, with patients with some cancers (eg, breast, head and 
neck, and malignant melanoma) reporting high depression levels, despite often 
greater needs in patients with other diseases (eg, lung cancer).66 Indeed, there may be 
little conceptual or statistical equivalence between the same measures used in 
different populations,34 putting some groups at risk of receiving inappropriate 
services if screening programs are used to determine access.6,34 
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Meta-review limitations 
Meta-reviews can overlook newly published papers.27 The fact that CAT measures 
were not captured demonstrates that there may be newer, but well-validated, 
measures that have not yet generated enough research to have been captured in a 
review.27,67 The PHQ-9 is another good example, because while it was reviewed less 
favourably in this meta-review, recent research suggests it may be a promising 
screener12 and case-finder,68 and may be quite responsive.69 The captured reviews 
also provided different data and used different methods, making it difficult to draw 
firm conclusions, however future meta-reviews could utilize more sophisticated tools 
(such as Rasch measurement) to allow a common metric to be generated for different 
depression measures.70 There were also overlaps in some of the captured reviews, 
which may have meant that the views of some, more prolific, research groups were 
over-represented.27 Failure to capture non-English reviews was also a limitation. 
 
Conclusion 
Patient-report outcome measures can play an important role in cancer care, and when 
used appropriately, can serve as a cost-effective, equitable means of identifying 
patients in need of clinical assessment and treatment.4,6 Given that current clinician 
and researcher choice of depression measures can be arbitrary (based on popularity, 
familiarity, personal preference, or perceived relevance),8 there is a need for more 
consensus on optimal depression measures in cancer.5,20 It is not likely, however, 
that a single tool exists, or will be developed, that meets the needs of every clinical 
and research purpose.7 Despite this, there are still clear benefits to improving 
consistency in measurement across the field where possible.7 This meta-review 
highlights commonly recommended depression measures in cancer while giving due 
consideration to the limitations of the depression measurement field and to the 
limitations of individual measures. 
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Panel A:   
 
 
Search and selection criteria  
We identified eligible reviews by searching three electronic databases of peer-reviewed journals (Medline, EMBASE, and PsychInfo), limited to 
human studies published between 1999 and 2014. We used the following search terms in Medline: [oncol$ OR neoplasm OR cancer OR tumor 
OR tumour OR leuk$ OR haematol$ OR hematol$ OR palliative] AND [review OR meta-anal$ OR ‘literature review’ OR ‘systematic review’ 
OR ‘research synthesis’ or ‘narrative review’] AND [scale OR questionnaire OR measure OR survey] AND [reliability OR validity OR validation 
OR psychometric] AND [depression OR depressive]. The term ‘palliative care’ was included because the majority of palliative care patients are 
diagnosed with cancer.1 This search structure was then adapted to suit EMBASE and PsychInfo and re-run. We also identified reviews by 
searching two grey literature databases (OpenGrey and Grey Literature Report). We also searched the reports of the following relevant 
organizations: the National Institute for Health and Clinical Excellence, Cancer Australia, U.S. National Comprehensive Cancer Network, U.S. 
National Cancer Institute, Cancer Research UK). Due to its expanding coverage2 and growing role in academic work (particularly in facilitating 
article retrieval9,10), we also searched Google Scholar. The reference lists of identified reviews were also searched. 
 22 
Panel B:  
 Research in context 
Evidence before this study 
Patient-report depression measures are increasingly used in cancer care. It is unclear which measures perform best. Investigators therefore choose 
measures based on advice in the literature (which is often conflicting), or worse, based on popularity, familiarity or personal preference.  
Added value of this study 
This meta-review integrates the findings of all reviews about depression measure selection in cancer, published in the last 15 years. It identifies 
consensus and disagreements across reviews and provides guidance about the most, and least, recommended measures, organized by study goal 
and target population. 
Implications of all the available evidence 
No currently available depression measure performs well enough to meet the needs of every clinical practice or research study. It is critical that if 
investigators choose to undertake depression screening or case-finding, they utilize the best available measure for their population and study design 
while being cognizant of their limitations. In doing so, depression measurement will become more accurate and consistent. Improved awareness of 
measure limitations will facilitate a more sophisticated interpretation of the data provided by patient-report depression tools. 
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Figure 1: Search process and articles captured for the meta-review (as at 7th November 2014)  
Note. Databases were searched in the following order: EMBASE, PsychInfo and Medline  
(*Medline captured no additional abstracts that were not already captured by EMBASE and/or PsychInfo). 
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Figure 2: Depression measures specifically recommended or cautioned against (organized by goal) 
*recommended/cautioned against by one review; **recommended/cautioned against by two reviews; ***recommended/cautioned against by three or more reviews. 
HADS-D= Hospital Anxiety and Depression Scale-Depression subscale. HADS=Hospital Anxiety and Depression Scale. HADS-A= Hospital Anxiety and Depression Scale-Anxiety 
subscale. BDI=Beck Depression Inventory. DT=Distress Thermometer. CES-D=Center of Epidemiologic Studies-Depression. GHQ-28=General Health Questionnaire-28 items. 
BEDS=Brief Edinburgh Depression Scale. EDS=Edinburgh Depression Scale. BDI-II=Beck Depression Inventory-II. ZSDS=Zung Self-rating Depression Scale. POMS-37=Profile of 
Mood States-37 items. PHQ-9=Patient Health Questionnaire-9 items. MHI-38=Mental Health Inventoru-38 items.  
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Figure 3: Depression measures specifically recommended by, or cautioned against use (organized by target treatment phase/patient group) 
*recommended/cautioned against by one review; **recommended/cautioned against by two reviews; ***recommended/cautioned against by three or more reviews.  
HADS=Hospital Anxiety and Depression Scale. EDS=Edinburgh Depression Scale. DT=Distress Thermometer. BDI=Beck Depression Inventory. ZSDS=Zung Self-rating 
Depression Scale. GHQ-28=General Health Questionnaire-28 items. CES-D=Center of Epidemiologic Studies-Depression. PHQ-9=Patient Health Questionnaire-9 items 
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First author (year), 
country 
Type of 
review┼ 
Population Depression 
measures reviewed╪ 
Main aims of 
review§ 
Description PRISMA 
criteriad 
Carey et al 
(2012)19  
Australia 
Systematic 10 samples of cancer 
patients, mixed diagnoses, 
Europe and Asia 
HADS Screening Describes the findings and quality of ten HADS 
validation studies against the SCID. Compares 
validated cut points with current cut points used in 
prevalence studies. 
20 
Carlson and Bultz 
(2003)3 
United States 
Narrative Narrative review regarding 
all cancer patients 
BDI 
CES-D 
ZSDS 
 
General 
recommendation 
Provides general evaluation of commonly used 
measures, plus editorial comments. Highlights three 
depression specific measures. Other measures (eg, 
HADS) not evaluated for depression specifically. 
- 
Donovan et al 
(2014)45 
United States 
Systematic  Mixed cancer diagnoses 
and treatment stages 
DT  Screening Summarizes the translations and validations of the 
DT in cancer patients worldwide. Assesses the 
translated versions’ ability to detect clinically 
significant distress.  
21 
King et al (2005)11 
United States 
Narrative Narrative review of 
depression assessment in 
terminally ill older patients 
BDI 
CES-D  
EDS 
GDS 
HADS 
MEQ 
General 
recommendation 
Suggests all six measures have ‘some usefulness’. 
GDS highlighted as having fewer somatic items. No 
instrument is clearly preferred for use at end-of-life.  
- 
Krebber et al 
(2014)22 
Netherlands 
Systematic 211 samples of cancer 
populations, mixed 
diagnoses and treatment 
stages 
BDI 
BSI-18/53 
CES-D 
HADS-D 
Screening Assesss prevalence of depression in cancer patients 
assessed by diagnostic interview and patient-report 
measures, and examines differences in prevalence 
between measures, type of cancer and treatment 
stage.  
24 
Lloyd-Williams 
(2001)71 
United Kingdom 
Narrative Narrative review of 
depression in palliative 
care  
Top 6 of 8 
BDI 
EDS 
GHQ 
HADS 
MEQ 
ZSDS 
General 
recommendation  
Provides a review of frequently used screening tools 
and highlights their use in the detection of depression 
in palliative care. Suggests that BDI, ZSDS, HADS 
and EPDS are most appropriate as a screening in 
palliative care.  
- 
Love (2004)72 
Australia 
 
Narrative Women with breast cancer Top 6 of 36 
BDI-SF 
BSI-18 
BSI-5 
GHQ-12  
GHQ-30 
HADS 
General 
recommendation  
Review 36 measures of depression or general 
distress. Recommends the BDI-SF as the most 
appropriate screening tool to detect depression in a 
clinical setting, as well as several other measures 
which are suitable for varying applications. 
- 
(Continues on next page)  
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First author 
(year), country 
Type of 
review * 
Population Depression 
measures reviewed ┼ 
Main aims of 
review ╪ 
Description PRISMA 
criteria§ 
Luckett et al 
(2010)5  
 
Australia 
 
Systematic 42 samples of patients 
receiving treatment, mixed 
diagnoses 
Top 6 of 16  
BSI-18/53 
CES-D  
DT  
HADS  
POMS-37/65 
SCL-90-R 
Sensitivity to 
change 
Reviews measures to assess distress (including 
depression) in RCTs of psycho-oncology 
interventions published between 1999-2009. 
Measures were filtered for initial suitability and then 
evaluated for reliability, validity and capacity to 
detect intervention effects.  
20 
Mitchell (2010)43 
United Kingdom 
Systematic Cancer  and palliative 
populations 
45 short tools, many 
depression focused, 
including 
DT, HADS and PDI 
Screening 
Case-finding 
Examines the merits of short and ultra-short measures 
(1-14 items) which have been validated against 
defined distress in cancer/palliative care, and 
compares single and multiple administrations. 
22 
Mitchell et al 
(2010)44 
United Kingdom 
 
Systematic 24 samples of cancer and 
palliative populations, 
mixed diagnoses 
24 studies testing 
HADS against 
clinical interview.  
 
Screening 
Case-finding 
Examines the diagnostic validity of the HADS-D, 
HADS-A and HADS-T in identifying depression, 
anxiety and distress in cancer. Highlights the 
sensitivity and specificity of subscales, real world 
comparison of methods and application of each 
subscale.  
22 
Mitchell et al 
(2012)7  
United Kingdom 
Systematic 33 samples of cancer and 
palliative populations, 
mixed diagnoses 
BDI-II 
DT 
EDS 
HADS-A 
HADS-D 
HADS-T 
Screening 
Case-finding 
Reviews the validity of screening and case-finding 
depression measures in cancer using a standardized 
rating system for validity and acceptability.  All 
studies assessed for quality. 
26 
Morse et al 
(2005)46 
United Kingdom 
Systematic  10 samples of 
cancer/palliative 
populations, mixed 
diagnoses/stages  
HADS Screening Examines the sensitivity and specificity of the 
HADS-D when compared with a clinical interview, 
from 10 primary studies. Also compares cut-points 
and prevalence between studies.  
13 
Wilson et al 
(2000)15 
United States 
Narrative 20 samples of advanced 
cancer/palliative cancer 
patients, mixed diagnoses. 
Top 6 of 7 
BDI-SF  
DT  
EDS 
HADS 
RSCL 
VAS 
General 
recommendation 
Provides an overview of depression assessment 
(diagnostics interviews and patient-report measures) 
in palliative care in cancer, and the discusses 
challenges in the assessment of depression in 
palliative care. 
- 
 (Continues on next page)  
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First author 
(year), country 
Type of 
review * 
Population Depression 
measures reviewed ┼ 
Main aims of 
review ╪ 
Description PRISMA 
criteria§ 
Ziegler et al 
(2011)73 
United Kingdom 
Systematic 22 samples of cancer 
populations across the 
trajectory (before, during 
and after treatment, 
palliative) 
Top 2 for each time-
point  
Pre treatment/ 
BDI, HADS 
During treatment 
HADS, MHI-5 
Post treatment 
BDI, HADS 
Palliative care  
BDI, BEDS 
Screening Assesses the performance of measures across the 
cancer trajectory, and the feasibility of measures for 
use within palliative populations. 48 measures 
captured assessing psychological distress, with only 
18 of these reporting trajectory stage. 
21 
 
Note: Only patient-reported outcome measures in survey/questionnaire format were included. ‘HADS’ has been used to refer to all subscales (HADS-D, HADS-A, HADS-T)  
 
*Reviews were classified as either a narrative or systematic review. ┼For studies that reviewed more than six measures, the top six recommended measures were included in the 
table in alphabetical order. ╪Main aims of systematic reviews were categorized as evaluating measures for screening, case-finding, and/or detecting change in depression. §See 
appendix for line-by-line critical appraisal of each systematic review. HADS=Hospital Anxiety and Depression Scale. SCID=Structured Clinical Interview for DSM-IV. 
BDI=Beck Depression Inventory. CES-D=Center of Epidemiologic Studies-Depression. ZSDS=Zung Self-rating Depression Scale. DT=Distress Thermometer. EDS=Edinburgh 
Depression Scale. GDS=Geriatric Depression Scale. MEQ=Mood Evaluation Questionnaire. BSI-18/53=Brief Symptom Inventory-18/53 items. HADS-D=Hospital Anxiety and 
Depression Scale-Depression Subscale. GHQ=General Health Questionnaire. BDI-SF=Beck Depression Inventory-Short Form. BSI-5=Brief Symptom Inventory. GHQ-
12=General Health Questionnaire-12. GHQ-30=General Health Questionnaire-30. POMS-37/65=Profile of Mood States. SCL-90-R=Symptom-Checklist-90-Revised. 
PDI=Psychological Distress Inventory. HADS-A=Hospital Anxiety Depression Scale-Anxiety subscale. HADS-T=Hospital Anxiety Depression Scale-Total. BDI-II=Beck 
Depression Inventory-II. RSCL=Rotterdam Symptom Checklist. VAS=Visual Analogue Scale. MHI-5=Mental Health Inventory-5 items. BEDS=Brief Edinburgh Depression 
Scale. 
 
Table 1. Summary of captured reviews of depression measures in cancer 
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Author  
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Total 
Carey (2012)19   x x x  x x x x x x x x x  x x x x x x  x x  x x 22 
Luckett (2010)5  x x x x  x x  x x x  x x  x x x  x x  x x x x  20 
Mitchell (2010)43 x x x x  x x x x x x  x x x x x x  x x x x x  x  22 
Mitchell (2010)44 x x x x  x x x x x x  x x x x x x  x x x x x  x x 23 
Mitchell (2012)7  x x x x  x x x x x x x x x  x x x  x x  x x x x x 23 
Nelson (2010)42  x x x x  x x x x x   x x  x x x   x  x x x x x 20 
Thekkumpurath (2008)1  x x x x  x x x x x x  x x  x x x  x x  x x  x  20 
Vodermaier (2009)4 x x x x  x x x x x x x x x x x x x x x x x x x x x x 26 
Ziegler (2011)73 x x x x  x x  x x x  x x  x x x  x x  x x x x x 21 
Morse (2005)46   x x x  x x  x        x x  x x  x x  x  13 
Donavon (2014)45  x x x  x x x x x x  x x x x x x  x x  x x x x  21 
Krebber (2014)22 x x x x  x x x x x x x x x  x x x x x x  x x x x x 24 
 
Note: The 27-item checklist comprises the following summarized checkpoints (‘x’ if the captured review met this criterion): 1: Title: Identify as systematic review, meta-
analysis, or both. 2: Structured summary: Provide a structured summary. 3: Rationale: Describe the rationale for the review. 4: Objectives: Provide an explicit statement of questions 
being addressed. 5: Protocol and registration details. 6: Eligibility criteria. 7: Information sources: Describe all information sources in the search and date last searched. 8: Search: 
Present full electronic search strategy for at least one database. 9: Study selection: State the process for selecting studies. 10: Data collection process: Describe method of data 
extraction. 11: Data items: List and define all variables for which data were sought. 12: Risk of bias in individual studies: Describe methods used for assessing risk of bias. 13: 
Summary measures: State the principal summary measures. 14: Synthesis of results: Describe the methods of handling data and combining results of studies. 15: Risk of bias across 
studies: Specify any assessment of risk of bias that may affect the cumulative evidence. 16: Additional analyses: Describe methods of additional analyses. 17: Study selection: Give 
numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage. 18: Study characteristics: For each study, present 
characteristics for which data were extracted. 19: Risk of bias within studies: Present data on risk of bias of each study. 20: Results of individual studies: Provide: summary data for 
each intervention group, effect estimates and confidence intervals. 21: Synthesis of results: Present results of each meta-analysis done. 22: Risk of bias across studies: Present results 
of any assessment. 23: Additional analysis: Give results of additional analyses, if done. 24: Summary of evidence: Summarize the main findings; consider their relevance to key 
groups. 25: Limitations: Discuss limitations at study and outcome level and at review-level. 26: Conclusions: Provide interpretation of results in the context of other evidence, and 
implications for future research. 27: Funding: Describe sources of funding. 
 
Table 2. Assessment of captured reviews, using the PRISMA 27-item checklist
 30 
First author 
(year), 
country 
Criterion 
measure/ 
reference 
standard 
Reported sensitivity (ranges) ┼ Reported specificity (ranges) ┼ Other data Findings/ 
recommendations 
Conclusion/ 
comments 
Carey et al 
(2012)19  
Australia 
 
SCID HADS threshold for major 
depression:  
Median (standard deviation)  
HADS-A≥7: 0·82 (0·17) 
HADS-A≥9: 0·87 (0·70-0·95)* 
HADS-A≥11: 0·62 (0·11)  
 
HADS-D≥5: 0·88 (NR) 
HADS-D≥7: 0·82 (0·17) 
HADS-D≥9: 0·86 (0·10) 
HADS-D≥10: 0·82 (NR)  
 
HADS-T≥15: 0·87 (0·70-0·95)* 
HADS-T≥17: 0·71 (0·07) 
HADS-T≥19: 0·76 (0·08) 
HADS threshold for major depression 
Median (standard deviation) HADS-
A≥7: 0·83 (0·12) 
HADS-A≥9: 0·83 (0·78-0·86)* 
HADS-A≥11: 0.84 (0.11)  
 
HADS-D≥5: 0·60 (NR)  
HADS-D≥7: 0·73 (NR) 
HADS-D≥9: 0·76 (0·10) 
HADS-D≥10: 0·95 (NR)  
 
HADS-T≥15:0.85 (0.81-0.89)* 
HADS-T≥17: 0.8 (0.05)  
HADS-T≥19: 0.86 (0.15) 
NR None of the validation 
studies met all five 
criteria for selection of a 
screening measure. 
Showed that the most 
commonly used cut 
points are not well 
supported by validation 
studies, with studies 
recommending cut points 
as varied as 5 to 10 for 
the HADS-D.  
Recommend caution in 
use of HADS due to 
variability of 
thresholds across 
studies. 
Donovan et 
al (2014)45 
United 
States 
HADS, 
BSI-53, 
Psychiatric 
DSM 
diagnosis  
Median (range; standard deviation)  
DT: 0·83 (0·50-1·00; 0·11)  
 
Median (range; standard deviation)  
DT: 0·68 (0·28-0·98; 0·16)  
Area under curve 
(ROC analysis)  
Median (range)  
DT: 0·79 (0·47-0·90) 
 
There is a lack of 
agreement regarding cut-
point for clinically 
significant distress. Most 
commonly identified cut-
point was 4 (52% of 
studies use this score).  
While the DT has 
widespread acceptance 
as a brief screening 
measure, different 
language versions 
should be used with 
caution due 
inconsistent cut-points. 
Krebber et 
al (2014)22 
Netherlands 
Robust 
DSM or 
ICD 
psychiatric 
diagnosis  
NR NR Mean prevalence of 
depression 8-24% in 
cancer patients 
HADS-D≥8: Pooled 
mean=0·18 (0·16-0·20) 
HADS-D≥11: Pooled 
mean=0·07 (0·06-0·08) 
CES-D≥16: Pooled 
mean=0·24 (0·21-0·26) 
Prevalence of depression 
varies significantly by 
measure used, type of 
cancer and treatment 
stage. Prevalence of 
major depression was 
higher when patient-
report instruments were 
used compared with 
diagnostic interview.  
Patient-report measures 
may overestimate the 
presence of depression. 
Caution needs to be 
taken at different 
treatment stages and 
for different types of 
cancer.  
(Continues on next page)  
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First author 
(year), 
country 
Criterion 
measure/ 
reference 
standard 
Reported sensitivity (ranges) ┼ Reported specificity (ranges) ┼ Other data Findings/ 
recommendations 
Conclusion/ 
comments 
Mitchell 
(2010)43  
United 
Kingdom 
 
 
 
Interview 
defined 
distress   
Not reported for depression alone. 
Weighted specificity  
(95% CI):  
DT: 0·79 (0·70-0·86) 
HADS: 0·70 (0·56-0·83)  
PDI: 0·68 (0·54-0·79) 
Not reported for depression alone 
Weighted specificity 
(95% CI):  
DT: 0·67 (0·60-0·74) 
HADS: 0·81 (0·73-0·87)  
PDI: 0·90 (0·82-0·95) 
Screening utility 
index 
DT: 0·682 
HADS: 0·662 
PDI: 0·667 
Out of >45 measures, these 
depression focused tools 
were categorized as having 
diagnostic 
accuracy/validity: BDI-SF, 
EDS, HSF, HSI, BEDS, 
BCFD, PHQ-1, PHQ-2, 
HADS-D. The HADS, DT, 
PDI and DT+IT had 
comparable accuracy.  
Given comparable 
performance, measure 
choice can be guided 
by acceptability or 
cost-effectiveness. 
Although short and 
ultra-short measures 
are useful, they should 
not be relied on in 
isolation.  
Mitchell et al 
(2010)44  
United 
Kingdom  
 
 
Psychiatric 
diagnosis 
with DSM 
or ICD 
Weighted specificity  
(95% CI):  
HADS-A: 0·81 (0·74-0·86) 
HADS-D: 0·72 (0·55-0·85) 
HADS-T: 0·82 (0·74-0·89)  
 
Weighted specificity 
(95% CI):  
HADS-A: 0·78 (0·66-0·88)  
HADS-D: 0·83 (0·74-0·90) 
HADS-T: 0·77 (0·63-0·89)  
 
Screening utility 
index: 
HADS-A: 0·75 
(good)  
HADS-D: 0·79 
(good)  
HADS-T: 0·74 
(good) 
 
HADS-T, HADS-D and 
HADS-A performed 
adequately as screeners. 
Clinical utility index for 
syndromal depression 
screening (UI-) was ‘good’ 
for all three. HADS 
appeared to perform 
marginally better in non-
palliative settings. 
HADS-T and HADS-A 
performed better than 
HADS-D, however 
considering clinical 
utility, all three 
subscales were equally 
recommended. HADS 
acceptability limited by 
its length, reverse 
worded items and mix 
of anxiety and 
depression symptoms. 
Mitchell et al 
(2012)7  
United 
Kingdom  
 
 
Psychiatric 
diagnosis 
with DSM 
or ICD 
Pooled weighted sensitivity across 
cancer populations  
(95% CI):   
BDI-II: 0·84 (0·65-0·96) 
DT: 0·80 (0·76-0·85) 
EPDS: 0·67 (0·52-0·80) 
HADS-A: 0·77 (0·69-0·84)  
HADS-D: 0·67 (0·55-0·78) 
HADS-T: 0·76 (0·70-0·82) 
Pooled weighted specificity across 
cancer populations  
(95% CI):  
BDI-II: 0·87 (0·83-0·91)  
DT: 0·71 (0·64-0·78)  
EPDS: 0·85 (0·79-0·90)  
HADS-A: 0·84 (0·72-0·93)  
HADS-D: 0·83 (0·76-0·90)  
HADS-T: 0·79 (0·60-0·94)  
Screening utility 
index, 
recommendation 
grade: 
BDI-II: 0·82, C  
DT: 0·71, C  
EPDS: 0·65, C  
HADS-A: 0·71, C  
HADS-D: 0·65, C 
HADS-T: 0·69, C  
BDI-II performed 
adequately (but had lower 
acceptability). In advanced 
cancer, two-stem questions 
rated highest. Across 
groups, two verbal 
questions graded highest. 
HADS-A had moderate 
performance (above some 
depression-specific 
measures).  
Optimal tool for 
screening appears to be 
two stem questions. 
BDI-II appeared to be 
best performing paper 
questionnaire. Omitting 
somatic symptoms did 
not appear to improve 
performance. 
(Continues on next page)  
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First author 
(year), 
country 
Criterion 
measure/ 
reference 
standard 
Reported sensitivity (ranges) ┼ Reported specificity (ranges) ┼ Other data Findings/ 
recommendations 
Conclusion/ 
comments 
Nelson et al 
(2010)42 
United States  
NR NR NR BDI-II, CES-D, 
ZSDS have been 
most extensively 
tested in geriatrics 
(although CES-D 
assesses less common 
symptoms in the 
elderly).  PHQ-9 and 
BDI-II have longer 
recall periods (2 
weeks), which may 
be too long for 
geriatric patients. 
Many measures are 
validated in geriatric adults 
and cancer patients; 
however, no psychometric 
information was identified 
for geriatric cancer 
patients. Little validation 
data available on GDS-15, 
however GDS-30 is more 
extensively tested. 
CES-D may be the 
most appropriate for 
elderly cancer patients. 
Further validation of 
depression measures 
for elderly needed. 
 
Thekkump-
urath et al 
(2008)74  
United 
Kingdom  
 
 
Psychiatric 
diagnosis 
with DSM, 
ICD or 
WHO 
Top 6 of 10  
Median (standard deviation) 
BDI-SF: 0·79 (NR)  
BEDS: 0·72 (NR) 
EDS: 0·71 (0·01) 
GHQ: NR 
HADS: 0·77 (0·04) 
MEQ: NR 
 
Top 6 of 10  
Median (standard deviation) 
BDI-SF: 0·71 (NR)  
BEDS: 0·83 (NR) 
EDS: 0·08 (0·04) 
GHQ: NR  
HADS: 0·69 (0·03)  
MEQ: NR 
 
VAS performed 
poorly compared with 
other measures. EDS 
fairs well, but needs 
further evaluation. 
BEDS is promising. 
HADS total score 
recommended as an 
indicator of general 
distress, but not in 
palliative care.  
Few studies have 
examined the validity 
of measures against 
structured interview in 
palliative care. 
Unidimensional tools 
are appealing due to 
reduced respondent 
burden in palliative 
care. 
Vodermaier 
et al (2004)4  
Canada 
 
 
 
 
Variable- 
interviews 
and 
questionna
ires 
Top 6 of 33 
Median (range; standard deviation)  
BDI: 0·89 (0·52-0·92; 0·19) 
BSI-18:0·94 (0·91-0·97; 0·04) 
CDQ: 0·96 (0·68-1·00; 0·15) 
CES-D: 1·0 (1·0-1·0; 0) 
GHQ-28: 0·84 (0·75-0·93; 0·13) 
HADS: 0·73 (0·16-1·0; 0·17) 
 
Top 6 of 33 
Median (range; standard deviation)  
BDI: 0·93 (0·9-1·0; 0·05) 
BSI-18: 0·89 (0·85-0·93; 0·06) 
CDQ: 0·9 (0·68-0·98; 0·13) 
CES-D: 0·82 (0·79-0·85; 0·04)  
GHQ-28: 0·92 (0·92-0·92; 0) 
HADS: 0·77 (0·4-1·0; 0·14)  
 
 
Overall judgement: 
BDI=Excellent 
BSI-18=Good 
CDQ=Excellent 
CES-D=Excellent 
GHQ=Excellent 
HADS=Good 
 
 
Ultra short: CDQ 
performed best.  
Short: CES-D (particularly 
CES-D negative affect 
scale) judged ‘excellent’. 
HADS was adequate, 
especially before and after 
treatment. HADS cuts offs 
variable.  
Long: BDI and GHQ-28 
met all evaluation criteria. 
No ultra short paper 
measures were 
recommended. CES-D 
recommended as best 
short measure, 
followed by HADS. 
HADS-T might be 
better than subscales in 
non-psychiatric 
patients. BDI and 
GHQ-28 were best 
long measures. 
(Continues on next page)  
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Ziegler et al 
(2011)73  
United 
Kingdom  
 
 
SCID See paper for detailed sensitivity and specificity data across all time points and measures.  
T1: HADS recommended (English, Japanese, Italian). Subscale cut-points ranged between 4-8, and 
11-19 for total score. BDI-SF: ‘very good’ sensitivity, acceptable specificity. ZDSD: poor 
sensitivity, good specificity.  
 
T2: HADS plus MHI-5 recommended to screen for clinically significant distress. GHQ-28 
demonstrated excellent sensitivity and specificity for psychosocial morbidity, however not 
recommended as a preferred option due to lack of recent validation studies.  
 
T3: HADS recommended with adequate sensitivity and specificity. BDI adequate sensitivity, lower 
specificity.  
 
T4: BEDS recommended (cut-point: 6). BDI (cut-point: 4): good sensitivity, low specificity. 
HADS did not perform adequately. 
HADS was most often 
used. Recommended use 
of HADS-T if used in 
palliative population. No 
single measure supported 
for use throughout 
trajectory. Feasibility and 
respondent burden also 
important considerations. 
Cost of HADS may need 
to be considered. 
HADS recommended 
for depression pre and 
post treatment, 
especially given its 
feasibility and 
acceptability (however 
appropriate cut-point 
varied). During 
treatment, HADS best 
if administered with 
MHI-5. During 
palliation/relapse, 
BEDS performed best 
in identifying 
depression. 
 
Note: ‘HADS’ has been used to refer to ‘HADS-A’, ‘HADS-D’ and ‘HADS-T’ 
*where the threshold was found in only 1 study, the range from the study was reported where possible. ┼For studies that reviewed more than six measures, the top six 
recommended measures were included in the table in alphabetical order. T1=Pretreatment/diagnosis.T2=Active treatment. T3=Post treatment. T4=Palliative care  
 
SCID=Structured clinical interview for DSM-IV. HADS=Hospital Anxiety and Depression Scale. HADS-A=Hospital Anxiety and Depression Scale -Anxiety subscale. HADS-
D=Hospital Anxiety and Depression Scale -Depression subscale. HADS-T=Hospital Anxiety and Depression Scale – Total. BSI-53= Brief Symptom Inventory-53 items. 
DSM=Diagnostic and Statistical Manual. DT=Distress Thermometer. ICD=International Classification of Disease. NR=Not reported, or only one study examined the measure so 
not data available. CES-D=Centre for Epidemiologic Studies-Depression Scale. PDI=Psychological Distress Inventory.  BDI-SF=Beck Depression Inventory-Short From. 
EDS=Edinburgh Depression Scale. HSF=Hornheide Short Form. HIS=Hornheide Screening Instrument. BEDS=Brief Edinburgh Depression Scale. BCFD=Brief Case-find for 
Depression. PHQ-1/2=Patient Health Questionnaire-1/2 items. DT+IT=Distress Thermometer with Impact Thermometer. UI-=Negative Utility Index. BDI-II= Beck’s Depression 
inventory-II. EPDS=Edinburgh Postnatal Depression Scale. ZSDS=Zung Self-Rating Depression Scale. PHQ-9. GDS-15/30=Geriatric Depression Scale-15/30  items. 
WHO=World Health Organization, GHQ=General Health Questionnaire. MEQ=Mood Evaluation Questionnaire. BDI=Beck Depression Inventory. BSI-18=Brief Symptom 
Inventory-18 items. CDQ=Combination Depression Question. GHQ-28=General Health Questionnaire-28 items. MHI-5= Mental health inventory-5 items. 
 
 
Table 3. Measures for depression screening: Reviews meeting at least 20 PRISMA criteria 
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Author [type of 
review], country 
Criterion measure/ 
reference standard 
Case-finding  
AUC (UI+)  
Case-finding 
Grade of 
recommendation 
Other 
data 
Findings/recommendations Conclusion/comments 
Mitchell (2010)43 
United Kingdom  
  
Semi-structured 
interview  
DT: 0·643 
HADS-T: 0·70  
PDI: 0·787 
 
NR  See 
table 2 
 
Data on short/ultra-short measures 
is too in complete to make 
recommendation 
Accuracy of short and ultra-short tools 
is modest, but these measures should 
not be solely relied on. Comparison of 
HADS, PDI, GHQ-12 and DT 
suggested similar screening capacity 
for general distress, thus choice of tool 
should be based on cost and 
acceptability.   
Mitchell et al 
(2010)44  
United Kingdom  
 
 
Robust psychiatric 
diagnosis according to 
the DSM or ICD 
HADS-A: 0·28  
HADS-D: 0·27 
HADS-T: 0·29 
HADS-A: Poor 
HADS-D: Poor 
HADS-T: Poor 
 
See 
table 2 
 
HADS-T, HADS-D and HADS-A 
performed poorly in case-finding. 
Clinical utility index for case 
finding (UI+) was ‘poor’ for the 
scales, 
HADS-T, HADS-D and HADS-A are 
likely to be suitable for screening for 
depression in cancer (not case-finding). 
 
Mitchell et al 
(2012)7  
United Kingdom 
 
 
Robust psychiatric 
diagnosis according to 
the DSM, ICD or 
WHO 
BDI-II: 0·78 
DT: 0·66 
EDS: 0·73 
HADS-D: 0·72 
BDI-II: C 
DT: C 
EDS: C 
HADS-D: C 
See 
table 2 
 
BDI-II has level 2 evidence, but 
with low acceptability). In non-
palliative settings, one question 
approach was graded highest for 
case-finding. 
Optimal tool for case-finding appears 
to be one or two verbal questions. BDI-
II appeared to be best performing paper 
questionnaire. Optimal tool for 
screening and case-finding appears to 
be two stem questions. BDI-II 
appeared to be best performing paper 
questionnaire. 
 
DT=Distress Thermometer. HADS-T=Hospital Anxiety and Depression Scale-Total. PDI=Psychological Distress Inventory. NR=Not reported, or only one study examined the 
measure so not data available. GHQ-12=General Health Questionnaire-12 items. DSM=Diagnostic and Statistical Manual. ICD=International Classification of Disease. HADS-
A=Hospital Anxiety and Depression Scale-Anxiety subscale. HADS-D=Hospital Anxiety and Depression Scale-Depression subscale. UI+=Positive utility index. WHO=World 
Health Organization. BDI-II=Beck Depression Inventory-II. EDS=Edinburgh Depression Scale.  
 
 
Table 4. Detailed summary of reviews of measures for depression case-finding meeting a minimum of 20 criteria outlined in the PRISMA 
Statement 
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Author (year), 
country 
Weighted score for 
assessing depression (max 
100)a 
Depression effect sizes 
Median (standard deviation)a 
Findings/recommendations Conclusion/comments 
Luckett et al 
(2010)5  
Australia  
 
 
 
Top 6 of 16 
BSI-18/53: 50 
CES-D: 55 
DT: 40 
HADS:77.5 
POMS-37/65: 60/55 
SCL-90-R: 47·5 
 
Top 6 of 16 
BSI-18/53: -1·85 (1 study only) 
CES-D: -0·21 (0·34) 
DT: 0·32 (1 study only)  
HADS: -0·5 (0·27) 
POMS-37/65: -0·24 (0·37) 
SCL-90-R: -0·205 (0·05) 
 
CES-D and HADS have frequently been used to detect 
change for RCTs, 21 and 20 times respectively for this 
review. ABS, BAI, BDI-Primary Care, DASS, DABS, GDS, 
GHQ-30/60, HDRS, MHI-18, PHQ-2, PHQ-9, PANAS, 
POMS-10/30/Bipolar, STAI and VAS were excluded in 
initial filter due to lack of evidence for psychometric 
properties in English-speaking cancer populations or due to 
somatic emphasis. BSI-18, GHQ-28, MHI-38, SCL-90 
received low scores, and were not recommended. Highest 
scoring measures were HADS, POMS-37/65 and CES-D. 
HADS-D and POMS-37 criticized for emphasis on 
anhedonia.  
HADS-D may be less suitable 
for patients with advanced 
cancer and for detecting minor 
depression. Recommend using 
HADS-D, HADS-A and HADS-
T where mixed affective 
disorders are the outcome of 
interest. CES-D recommended 
if depression is the sole focus. 
 
a For studies that reviewed more than six measures, the top six recommended measures were included in the table in alphabetical order 
 
BSI-18/53=Brief Symptom Inventory-18/53 items. CES-D=Center of Epidemiologic Studies-Depression. DT=Distress Thermometer. HADS=Hospital Anxiety and Depression 
Scale. POMS-37/65=Profile of Mood States-37-65 items. SCL-90-R=Symptom Checklist-90-Revised. RCT=Randomized Controlled Trial. ABS=Affect Balance Scale. BAI=Beck 
Anxiety Inventory. BDI-Primary Care=Beck Depression Inventory-Primary Care. DASS=Depression Anxiety Stress Scale. DABS=Derogatis Affect Balance Scale. 
GDS=Geriatric Depression Scale. GHQ-30/60=General Health Questionnaire-30/60 items. HDRS=Hamilton Depression Rating Scale. MHI-18=Mental Health Inventory-18. 
PHQ-2=Patient Health Questionnaire-2 items. PHQ-9=Patient Health Questionnaire-9 items. PANAS=Positive and Negative Affect Scale. POMS-10/30/Bipolar=Profile of Mood 
States-10/30/Bipolar items. STAI=State-Trait Anxiety Inventory. VAS=Visual Analogue Scale.GHQ-28=General Health Questionnaire-28 items. MHI-38=Mental Health 
Inventory-38 items. SCL-90=Symptom Checklist-90 items. POMS-37/65=Profile of Mood states-37/65 items. HADS-D=Hospital Anxiety and Depression Scale-Depression 
Subscale. HADS-A=Hospital Anxiety and Depression Scale-Anxiety Subscale. HADS-T=Hospital Anxiety and Depression Scale-Total.  
 
Table 5. Detailed summary of reviews of measures used to detect change in interventions meeting a minimum of 20 criteria outlined in the 
PRISMA Statement. 
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Author (year), country Findings/recommendations Conclusion/comments 
Morse et al (2005)46 
United Kingdom 
Found that the HADS-D had a large degree of variability in sensitivity and specificity 
across a range of cancer populations.  HADS-D shows high sensitivity but much at the 
expense of false positives.  Cut-points for the HADS-D scale ranged from 5 to 11. 
Results of the review suggest a threshold of 8 to achieve high sensitivity, and lowering to 
5 for some cancer populations.  
Although HADS-D appears to be quite useful, it is suggested 
that no single tool can be used across treatment and disease 
pathway. Screening methods should be adapted according to 
location of assessment, stage of cancer (eg, use of HADS is 
not recommended in palliative care) and diagnosis.  
 
 
HADS-D=Hospital Anxiety and Depression Scale-Depression subscale. HADS=Hospital Anxiety Depression Scale 
 
Table 6. General findings of recommendation reviews meeting fewer than 20 criteria outlined in the PRISMA Statement. 
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Author [type of 
review], 
country 
Population Depression measures 
revieweda 
General description Findings/recommendations Conclusion/comments 
Carlson et al 
(2003)3  
United States 
  
All cancer  
patients 
Top 6 of 12 
BDI 
BSI-18/53 
CES-D 
GHQ-12/20/28/30/60 
HADS  
ZSDS 
Provides general evaluation of the 
psychometric properties of commonly 
in use, plus editorial comments. 
Highlighted three depression specific 
measures. Other measures (eg, HADS) 
not evaluated for capacity to assess 
depression specifically. 
CES-D described as ‘excellent’ in providing 
population-based assessment of depression. BDI 
described as ‘good’, focused purely on 
depression, but not highly responsive to change.  
GHQ is losing favour in psycho-oncology 
settings.  
CES-D received highest 
qualitative rating of depression 
specific measures. Review 
highlights potential for 
electronic administration of 
measures. 
King et al 
(2005)11 
United States 
  
 
Terminally ill 
older patients 
BDI-SF 
CES-D 
EDS 
GDS  
HADS 
MEQ 
 
HADS, EDS, GDS, MEQ, BDI, CES-
D have ‘some usefulness’. GDS 
highlighted as having fewer somatic 
items. 
The listed patient-report measures have ‘some 
usefulness’ in the older patient population, 
however they should be used cautiously. Existing 
studies found to be unable to differentiate 
between measures based on psychometric 
properties.  
Consider augmenting 
assessment with clinical 
interview. Possibly use 
measures to quantify severity of 
symptoms and change over 
time, rather than for case 
identification. 
Love (2004)72 
 
Australia 
 
Women with 
breast cancer  
Top 6 of 17 
BDI  
BDI-SF 
BSI-18 
BSI-53 
GHQ-12  
GHQ-30 
 
Provides a summary of patient-report 
screening tools used for psychological 
distress in women with breast cancer. 
Evaluated the psychometric properties 
and provided pros and cons of each 
measure.  
Found BDI-SF most appropriate tool to use to 
detect depression in a clinical setting. BSI-18 and 
GHQ-12 also recommended, although GHQ-12 
has not widely been used in cancer groups. 
Although CES-D has been widely used in cancer 
populations, it has limitations as a suitable choice 
for a screening tool. Similarly, HADS might not 
be suitable for screening for depression.  
The most suitable screening tool 
will depend on the intended use.  
BDI-SF was considered the 
most suitable screening tool to 
detect depression in a clinical 
setting.  
Pirl (2010)20  
United States  
 
Mixed 
diagnoses: all 
individuals 
with cancer 
BDI 
BDI-II 
BSI-18 
CES-D 
HADS 
PHQ-9 
 
Provides a narrative guide to the use of 
commonly used outcome measures in 
psycho-oncology. 
BDI described as widely used with cancer 
patients, although it contains some somatic items 
which may affect scores. BDI-II described as 
having ‘good performance’, easy to use, quick to 
complete and less emphasis on somatic 
symptoms. CES-D described as growing in 
popularity, with good validity/reliability in 
specific cancer patients (eg, breast). HADS has 
least focus on somatic symptoms. 
BDI, CES-D and HADS may all 
be reasonable depression 
screening measures in 
ambulatory cancer patients. 
(Continues on next page)  
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Author [type 
of review], 
country 
Population Depression measures 
revieweda 
General description Findings/recommendations Conclusion/comments 
Trask (2004)6 
United States 
  
 
Cancer 
patients of 
mixed 
diagnoses 
Top 6 of 10  
BDI  
CES-D  
GDS 
HADS 
RSCL 
ZSDS 
 
 Review aimed to provide a 
summary of the available means 
of assessing depression in cancer, 
including patient-report measures. 
HADS is most used and was explicitly developed for 
the medically unwell. Appropriate cut-points for 
HADS-T and HADS-D vary by study. If HADS is to 
be used, it should be followed by in-depth 
assessment. Large variability in sensitivity, 
specificity, misclassification rate and positive 
predictive value of each of the reviewed measures. 
HADS performs well in those who are disease free or 
have stable disease, but not with progressive cancer.  
Clinical interview still considered 
gold standard diagnostic tool. 
Depression measures for children 
and the elderly needed to be 
considered separately. 
Clear need for further research. 
Wilson et al 
(2000)15 
United States 
  
 
Palliative 
cancer 
patients, 
mixed 
diagnoses. 
Top 6 of 9 
BDI-SF 
DT 
EDS 
HADS 
PHQ-9 
 
Provides an overview of 
depression assessment in palliative 
care in cancer, including criterion-
based diagnostic systems (eg, 
DSM-IV) and patient-report 
scales. 
Although many depression measures in the literature, 
all those reviewed have been developed or tested 
with medical populations. None of the questionnaires 
provide perfect concordance with structured 
diagnostic interviews, with HADS showing twice the 
rates of “definite depression” than that reported in 
studies of diagnostic interviews. HADs however has 
outperformed GHQ in two studies. Optimal HADS 
cut-points vary between studies. Measures as VAS, 
such as the DT may be preferable in palliative care, 
although caution should be made as ‘distress’ does 
not indicate ‘clinical depression’.  
Given the necessary trade-off 
between sensitivity and specificity 
for all measures, practical 
considerations also important (eg, 
brevity). Outcomes measures can 
be useful when clinical interviews 
not feasible, however they are 
unlikely to match the diagnostic 
efficiency of a brief interview. 
Suggested that patient-report 
measures be used only as indices 
of general distress.  
 
Note: ‘HADS’ has been used to refer to ‘HADS-A’, ‘HADS-D’ and ‘HADS-T. 
a For studies that reviewed more than six measures, the top six recommended measures were included in the table in alphabetical order 
BDI=Beck Depression Inventory. BSI-18/53=Brief Symptom Inventory-18/53 items. CES-D=Center of Epidemiologic Studies-Depression. GHQ-12/20/28/30/60=General Health 
Questionnaire-12/20/28/30/60 items. HADS=Hospital Anxiety and Depression Scale. ZSDS=Zung Self-rating Depression Scale. GHQ=General Health Questionnaire. BDI-SF=Beck 
Depression Inventory-Short Form. EDS=Edinburgh Depression Scale. GDS=Geriatric Depression Scale. MEQ=Mood Evaluation Questionnaire. BDI-II=Beck Depression Inventory-II. 
PHQ-9=Patient Health Questionnaire-9 items. RSCL=Rotterdam Symptom Checklist. HADS-T=Hospital Anxiety and Depression Scale-Total. HADS-D=Hospital Anxiety and Depression 
Scale-Depression subscale. DT=Distress Thermometer.  
 
Table 7. General findings of narrative reviews 
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Measure Reviewed by Positive features Negative features 
BEDS 1,8 Screening:  
 Recommended for palliative care by two systematic reviews.1,8 
 
BDI 3-5,8,43 Screening:  
 Recommended by two narrative3,20 and two systematic4,43 reviews 
 ‘Easy to use’ and quick to complete,20 well tested in geriatric patients42 
 Recommended for older, terminally ill in one narrative review75 
 Recommended at diagnosis in one systematic review.8 
 Described as more accurate than the VAS in one narrative review15 
Case finding: 
 Adequate performance in one review43 
 Described as not highly responsive to change in narrative review3 
 Not recommended by systematic review due to low property scores5 
 Had lower acceptability scores than other short screening tools43 and is 
long4 
 Recall period may be too long for geriatric patients42 
 Contains some somatic symptoms20 
 Sensitivity appeared to decrease after treatment and during palliative 
care8 
CES-D 3,4,42 Screening: 
 Recommended for use in two narrative3,20 and two systematic4,5 reviews. 
 Recommended for older, terminally ill in one narrative review75 and well 
tested in geriatric patients42 
 Freely available and quick to complete20 
 Symptoms assessed not as well suited to geriatric patients.42 
EDS 1,75 Screening: 
 Described as having ‘some usefulness’ in narrative review for older, 
terminally ill75 
 Described as ‘fairing well’ in one systematic review in comparison to other 
tools in palliative care1 
 
GHQ-28 4 Screening: 
 Judged as ‘excellent’ in one systematic review.4 
 Is longer than other measures.4 
 
HADS 3-8,19,75 Screening: 
 One of the most widely used scales,6,8 allowing cross-study comparison.  
 Highest scoring measure in one systematic review,5 judged as ‘good’ by 
another.4 
 Highlighted as performing adequately as a screening tool (HADS-T, D and 
A)7 
 HADS-As performed moderately well in comparison to other short 
screening tools.43 
 Recommended at diagnosis, and post-treatment.8  
 Described as having ‘some usefulness’ in narrative review for older, 
terminally ill75 
 HADS-T, A and D performed poorly in case-finding.7  
 Most commonly used cut-point (8) not well supported in validation 
studies.4,6,8,15,19  
 Criticized for emphasis on anhedonia,5 although has less focus on somatic 
symptoms than other measures.20 
 Less suitable for advanced cancer,4,5 palliative care7,8 and for detecting 
minor depression.5 
 Performs less well during active treatment (unless combined with the 
MHI-5)8 
 Cost may be a barrier.8  
 Should be followed with clinical interview.6 
PHQ-9 4,5,42   Judged as ‘poor’ due to low reliability, low criterion measure and low 
validity.4 
 40 
 
 Length of recall (2-weeks) is quite burdensome for geriatric population.42 
 Multiple items problematic for those undergoing active treatment for 
cancer of any type and stage.5  
POMS-37  Screening: 
 High scoring measure in one systematic review.5 
 
ZSDS 3,8,42 Screening: 
 Described as ‘good’ in narrative review.3 
 One of the most tested in geriatric patients.42 
 Judged as having good specificity at diagnosis in one study.8 
 Judged as having poor sensitivity at diagnosis in one study.8 
 
Brief Edinburgh Depression Scale (BEDS); Beck Depression Inventory (BDI); Centre of Epidemiologic Studies-Depression (CES-D); Edinburgh Depression Scale (EPS); General Health 
Questionnaire-28 items (GHQ-28); Hospital Anxiety and Depression Scale (HADS); Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A); Hospital Anxiety and 
Depression Scale-Depression subscale (HADS-D); Hospital Anxiety and Depression Scale-Total (HADS-T); Mental Health Inventory-5 items (MHI-5); Patient Health Questionnaire-9 
items (PHQ-9); Profile of Mood States-37 items (POMS-37); Zung Self-rating Depression Scale (ZSDS)  
 
Table 8: Summary of positive and negative features of candidate measures  
  
 
